Clinical Trial Update: Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the immunogenicity, safety, and tolerability of two-dose regimens of adjuvanted and non-adjuvanted swine-origin A/H1N1 influenza va…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• A/H1N1 influenza vaccine (egg-derived) adjuvanted (Influenza vaccine)
• A/H1N1 influenza vaccine (egg-derived) non-adjuvanted (Influenza vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pandemic Influenza | Phase 3 | Status: COMPLETED